Head-to-head evidence
NNC0519-0130 vs tirzepatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
NNC0519-0130
Developed by Novo Nordisk
NCT06326060 · Phase 2 · completed
The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.
tirzepatide · Zepbound / Mounjaro
Marketed by Eli Lilly
NCT04184622 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial in 2,539 participants using percent change in body weight, the disease-defining endpoint for obesity, as the primary measure. All three tirzepatide doses produced significantly greater weight loss than placebo at 72 weeks.
Next expected readout: November 2026 · NCT07299084 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0519-0130's landscape · tirzepatide's landscape